Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy
Background It has been proposed that magnetic resonance imaging (MRI) be used to guide
breast cancer surgery by differentiating residual tumor from pathologic complete response …
breast cancer surgery by differentiating residual tumor from pathologic complete response …
[HTML][HTML] Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives …
M Kaufmann, G Von Minckwitz, HD Bear, A Buzdar… - Annals of …, 2007 - Elsevier
Neoadjuvant (primary systemic) treatment has become a standard option for primary
operable disease for patients who are candidates for adjuvant systemic chemotherapy …
operable disease for patients who are candidates for adjuvant systemic chemotherapy …
Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group
F Sardanelli, C Boetes, B Borisch, T Decker… - European journal of …, 2010 - Elsevier
The use of breast magnetic resonance imaging (MRI) is rapidly increasing. EUSOMA
organised a workshop in Milan on 20–21st October 2008 to evaluate the evidence currently …
organised a workshop in Milan on 20–21st October 2008 to evaluate the evidence currently …
Neoadjuvant chemotherapy for breast cancer: functional tumor volume by MR imaging predicts recurrence-free survival—results from the ACRIN 6657/CALGB 150007 …
Purpose To evaluate volumetric magnetic resonance (MR) imaging for predicting recurrence-
free survival (RFS) after neoadjuvant chemotherapy (NACT) of breast cancer and to …
free survival (RFS) after neoadjuvant chemotherapy (NACT) of breast cancer and to …
Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer: Translational …
JF De Los Santos, A Cantor, KD Amos, A Forero… - Cancer, 2013 - Wiley Online Library
BACKGROUND: Increased pathologic complete response (pCR) rates observed with
neoadjuvant chemotherapy (NCT) for some subsets of patients with invasive breast cancer …
neoadjuvant chemotherapy (NCT) for some subsets of patients with invasive breast cancer …
Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta …
Background Magnetic resonance imaging (MRI) may guide breast cancer surgery by
measuring residual tumor size post-neoadjuvant chemotherapy (NAC). Accurate …
measuring residual tumor size post-neoadjuvant chemotherapy (NAC). Accurate …
Dynamic contrast‐enhanced MRI in the diagnosis and management of breast cancer
LW Turnbull - NMR in Biomedicine: An International Journal …, 2009 - Wiley Online Library
Dynamic contrast‐enhanced MRI (DCE‐MRI) is an evolving tool for determining breast
disease, which benefits from the move to imaging at 3 T. It has major capabilities for the …
disease, which benefits from the move to imaging at 3 T. It has major capabilities for the …
Neoadjuvant therapy for breast cancer
The past few decades have seen an increase in both the role and the complexity of
neoadjuvant therapy for breast cancer. Neoadjuvant therapy was initially described as …
neoadjuvant therapy for breast cancer. Neoadjuvant therapy was initially described as …
TopoTxR: A topology-guided deep convolutional network for breast parenchyma learning on DCE-MRIs
Abstract Characterization of breast parenchyma in dynamic contrast-enhanced magnetic
resonance imaging (DCE-MRI) is a challenging task owing to the complexity of underlying …
resonance imaging (DCE-MRI) is a challenging task owing to the complexity of underlying …
MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy
JH Chen, B Feig, G Agrawal, H Yu… - … Journal of the …, 2008 - Wiley Online Library
BACKGROUND. This study investigated the role of magnetic resonance imaging (MRI) in
evaluation of pathologically complete response and residual tumors in patients who were …
evaluation of pathologically complete response and residual tumors in patients who were …